Total Body PET-CT Imaging of Prostate Cancer Using Illuccix

Status unconfirmed · Early Phase 1

Conditions studied: Metastatic Castration-resistant Prostate Cancer

In brief

Illuccix will be used per the prescribing instructions for PET-CT imaging on the United Imaging scanner uEXPLORER to establish a standard scanning protocol.

Key facts

Study ID

NCT05558956

Run by

BAMF Health

People needed

100

Starts

2022-11-01

Expected to finish

2023-12-01

Last updated by the study team

2023-07-27

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Provision of signed and dated informed consent form
• Male ≥ 18 years of age
• Patients meeting clinical need for Illuccix PET scan:
• Patients with suspected metastasis who are candidates for initial definitive therapy
• Patients with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
• Patient is physically able to lay flat for the PET-CT procedure

You may not qualify if…

• Assessment by the Investigator as unable or unwilling to comply with the requirements of the protocol.

Where it is running

• BAMF Health — Grand Rapids, Michigan, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.